ArcaScience, the AI Healthtech startup setting a new standard for benefit-risk evaluation to make better, safer drugs, has announced a $7 million seed funding round led by The Moon Venture, with participation from Pléiade Venture, Plug&Play Ventures, Bpifrance, and AKKA Technologies.

EnsiliTech, a Bristol-based BioTech startup, has secured €5.2 million in Seed funding to revolutionise the way life-saving medicines are stored and transported globally.

The round was led by Eos Advisory and joined by Calculus Capital, Empirical Ventures, Fink Family Office, QantX, Angel Investors Bristol (AIB), HERmesa, Penn Park Capital, chANGELS, and several individual angel investors.

Qured, the UK health technology company transforming workforce wellbeing through its Prevention-as-a-Service platform, has raised £620k in new funding via an Advanced Subscription Agreement (ASA). Investors include returning backer Lexham Partners, new VC investor Araya Ventures, angel syndicates Korra Ventures and LBS E100, as well as notable angels including Prof. Sneh Khemka CBE (Qured Chairman) and the majority of Qured’s existing minority investors.

Grace & Green, the trailblazing sustainable period care brand, has secured a significant milestone in its mission to revolutionise the hygiene industry with the close of a £1.3 million funding round, with support from Lifted Ventures. The round will accelerate the company's ambition to launch two world-first, patented R&D innovations in period and incontinence care.

Digostics, the UK-based health tech company behind the world's first oral glucose intolerance test (OGTT) that can be done at home instead of a clinic or hospital, has announced it has surpassed £500,000 in funding on the Crowdcube equity crowdfunding platform, with more than 100 investors backing the company's mission to revolutionise diabetes detection and monitoring.

Cumulus Neuroscience has closed a £3.5 million investment round. The funding round was led by a £1.5m investment from Whiterock's Growth Capital Fund, alongside £1.25m from the Investment Fund for Northern Ireland's equity fund, run by Clarendon Fund Managers, £0.3m from Angel CoFund and £0.2m from Co Fund NI.

Beverage and supplement brand Neutonic has raised £2.7 million in its first funding round. The investment, backed by a high-profile group including fitness influencer Kayla Itsines, and Grenade founder Alan Barratt, will accelerate Neutonic's mission to become a global leader in nootropics.

Anya, a HealthTech company utilising advanced AI to deliver personalised, 24/7 care to women, empowering them to take control of their health, has received investment from five Henley Business Angels members, contributing towards Anya's seed round and marking the network's second-largest investment in a company to date.

OutSee, a genomics and drug discovery company pioneering a unique AI-based predictive genomics approach to target discovery, has secured £1.8M in seed funding, led by Ahren Innovation Capital and with additional investment from Empirical Ventures, Kadmos Capital and Panacea Investment Group. The funds will support OutSee through the next phase of its growth strategy, with a focus on expanding the Company's in-house target discovery program and establishing new strategic partnerships with leading pharma and biotech companies.

Chesham-based startup, Flomark Ltd, has secured a £150,000 investment from British Design Fund (BDF) and £150,000 from Imperial College Enterprise Fund (ICEF) as part of a broader funding round, as it looks to accelerate the development of its pioneering solutions aimed at making IV drips safer for patients.

Marissa Krummrich, Investment Manager at b2ventures, explains the thinking behind leading Kiin Bio's $2.2m pre-seed round, with co-investment from Heartfelt, rule30 and angel investors. 

A pioneering Scottish technology that could dramatically speed up the development of life-saving cancer treatments has secured a £750,000 seed investment.  ScreenIn3D, a spin-out of the University of Strathclyde, has developed a groundbreaking "lab-on-a-chip" system that allows drug developers to test dozens of cancer therapies on tiny patient-derived tumour samples - offering a faster, easier and more accurate alternative to animal testing.